Story
Kodiak Sciences Stock Surges 90% on Positive Wet AMD Drug Trial Results
Summary
Shares of Kodiak Sciences soared in premarket trading after the company reported that its drug, Zenkuda, met its primary endpoint in a pivotal Phase 3 study for treating wet age-related macular degeneration.
Kodiak Sciences Inc. (NASDAQ:KOD) shares surged as much as 90% in premarket trading on Monday after the biopharmaceutical company announced positive top-line results from its Phase 3 DAYBREAK study. The trial evaluated its drug candidate Zenkuda for the treatment of wet age-related macular degeneration (wet AMD), a leading cause of vision loss.
Key Trial Results
The DAYBREAK study successfully met its primary endpoint, demonstrating that Zenkuda achieved non-inferiority in vision gains compared to aflibercept, a current standard-of-care treatment, at one year. The company reported a highly statistically significant result with a p-value of 0.0007.
A key finding for the drug's potential market differentiation was its dosing schedule. According to the results, 54% of patients were successfully maintained on a 6-month dosing interval. The study also showed that another of the company's candidates, tabirafusp-ted, met its vision and anatomical endpoints.
Safety Profile and Regulatory Path
AdKodiak reported a favorable safety profile for Zenkuda, with a 0% rate of intraocular inflammation and a 0.5% rate of cataract adverse events. This compared favorably to the aflibercept arm, which saw a 0.9% rate of cataract adverse events.
The company stated it plans to submit a multi-indication Biologics License Application (BLA) for Zenkuda to regulators in the fourth quarter of 2026. The submission will be supported by data from five positive Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion, signaling a broad potential application for the treatment.
Market Significance
The significant premarket stock rally reflects investor optimism that the positive Phase 3 data de-risks Zenkuda's path to potential regulatory approval and commercialization. A longer-acting treatment for wet AMD that reduces the frequency of injections is considered a significant unmet need, potentially offering greater patient convenience and improving treatment adherence compared to existing therapies.
Read next
More on Stocks
Haleon Placed on Negative Catalyst Watch by J.P. Morgan on Slowing Sales
J.P. Morgan placed consumer health firm Haleon on a negative Catalyst Watch, citing weak sales momentum that threatens the company's growth targets and prompts cuts to earnings forecasts and its price target.
American Express Expands Global Acceptance to 190 Million Merchant Locations
American Express announced its cards are now accepted at over 190 million locations worldwide, with international acceptance more than doubling in four years as it works to close the gap with rivals Visa and Mastercard.
NVIDIA Shares Rise on Record $150 Billion Share Buyback Increase
The chipmaker's stock climbed in pre-market trading after it unveiled the largest-ever increase to a share repurchase program, bringing its total authorization to $235 billion.
PepsiCo Downgraded by Deutsche Bank on Doubts Over North American Recovery
Deutsche Bank cut its rating on PepsiCo to 'Hold' from 'Buy,' citing concerns that the company's turnaround efforts in its food and beverage units are yielding only temporary benefits amid a challenging consumer environment.